Cargando…
Biomarkers of the L-Arginine/Dimethylarginine/Nitric Oxide Pathway in People with Chronic Airflow Obstruction and Obstructive Sleep Apnoea
Background: Chronic obstructive pulmonary disease (COPD) and obstructive sleep apnoea (OSA) are common chronic diseases that are associated with chronic and intermittent hypoxemia, respectively. Patients affected by the overlap of COPD and OSA have a particularly unfavourable prognosis. The L-argini...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10455103/ https://www.ncbi.nlm.nih.gov/pubmed/37629272 http://dx.doi.org/10.3390/jcm12165230 |
_version_ | 1785096366752530432 |
---|---|
author | Hannemann, Juliane Thorarinnsdottir, Elin H. Amaral, André F. S. Schwedhelm, Edzard Schmidt-Hutten, Lena Stang, Heike Benediktsdottir, Bryndis Gunnarsdóttir, Ingibjörg Gislason, Thórarinn Böger, Rainer |
author_facet | Hannemann, Juliane Thorarinnsdottir, Elin H. Amaral, André F. S. Schwedhelm, Edzard Schmidt-Hutten, Lena Stang, Heike Benediktsdottir, Bryndis Gunnarsdóttir, Ingibjörg Gislason, Thórarinn Böger, Rainer |
author_sort | Hannemann, Juliane |
collection | PubMed |
description | Background: Chronic obstructive pulmonary disease (COPD) and obstructive sleep apnoea (OSA) are common chronic diseases that are associated with chronic and intermittent hypoxemia, respectively. Patients affected by the overlap of COPD and OSA have a particularly unfavourable prognosis. The L-arginine/nitric oxide (NO) pathway plays an important role in regulating pulmonary vascular function. Asymmetric (ADMA) and symmetric dimethylarginine (SDMA) interfere with NO production. Methods: We analysed the serum concentrations of ADMA, SDMA, L-arginine, L-citrulline, and L-ornithine in a large sample of the Icelandic general population together with chronic airflow obstruction (CAO), a key physiological marker of COPD that was assessed by post-bronchodilator spirometry (FEV1/FVC < LLN). OSA risk was determined by the multivariable apnoea prediction (MAP) index. Results: 713 individuals were analysed, of whom 78 (10.9%) showed CAO and 215 (30%) had MAP > 0.5. SDMA was significantly higher in individuals with CAO (0.518 [0.461–0.616] vs. 0.494 [0.441–0.565] µmol/L; p = 0.005), but ADMA was not. However, ADMA was significantly associated with decreasing FEV1 percent predicted among those with CAO (p = 0.002). ADMA was 0.50 (0.44–0.56) µmol/L in MAP ≤ 0.5 versus 0.52 (0.46–0.58) µmol/L in MAP > 0.5 (p = 0.008). SDMA was 0.49 (0.44–0.56) µmol/L versus 0.51 (0.46–0.60) µmol/L, respectively (p = 0.004). The highest values for ADMA and SDMA were observed in individuals with overlap of CAO and MAP > 0.5, which was accompanied by lower L-citrulline levels. Conclusions: The plasma concentrations of ADMA and SDMA are elevated in COPD patients with concomitant intermittent hypoxaemia. This may account for impaired pulmonary NO production, enhanced pulmonary vasoconstriction, and disease progression. |
format | Online Article Text |
id | pubmed-10455103 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-104551032023-08-26 Biomarkers of the L-Arginine/Dimethylarginine/Nitric Oxide Pathway in People with Chronic Airflow Obstruction and Obstructive Sleep Apnoea Hannemann, Juliane Thorarinnsdottir, Elin H. Amaral, André F. S. Schwedhelm, Edzard Schmidt-Hutten, Lena Stang, Heike Benediktsdottir, Bryndis Gunnarsdóttir, Ingibjörg Gislason, Thórarinn Böger, Rainer J Clin Med Article Background: Chronic obstructive pulmonary disease (COPD) and obstructive sleep apnoea (OSA) are common chronic diseases that are associated with chronic and intermittent hypoxemia, respectively. Patients affected by the overlap of COPD and OSA have a particularly unfavourable prognosis. The L-arginine/nitric oxide (NO) pathway plays an important role in regulating pulmonary vascular function. Asymmetric (ADMA) and symmetric dimethylarginine (SDMA) interfere with NO production. Methods: We analysed the serum concentrations of ADMA, SDMA, L-arginine, L-citrulline, and L-ornithine in a large sample of the Icelandic general population together with chronic airflow obstruction (CAO), a key physiological marker of COPD that was assessed by post-bronchodilator spirometry (FEV1/FVC < LLN). OSA risk was determined by the multivariable apnoea prediction (MAP) index. Results: 713 individuals were analysed, of whom 78 (10.9%) showed CAO and 215 (30%) had MAP > 0.5. SDMA was significantly higher in individuals with CAO (0.518 [0.461–0.616] vs. 0.494 [0.441–0.565] µmol/L; p = 0.005), but ADMA was not. However, ADMA was significantly associated with decreasing FEV1 percent predicted among those with CAO (p = 0.002). ADMA was 0.50 (0.44–0.56) µmol/L in MAP ≤ 0.5 versus 0.52 (0.46–0.58) µmol/L in MAP > 0.5 (p = 0.008). SDMA was 0.49 (0.44–0.56) µmol/L versus 0.51 (0.46–0.60) µmol/L, respectively (p = 0.004). The highest values for ADMA and SDMA were observed in individuals with overlap of CAO and MAP > 0.5, which was accompanied by lower L-citrulline levels. Conclusions: The plasma concentrations of ADMA and SDMA are elevated in COPD patients with concomitant intermittent hypoxaemia. This may account for impaired pulmonary NO production, enhanced pulmonary vasoconstriction, and disease progression. MDPI 2023-08-11 /pmc/articles/PMC10455103/ /pubmed/37629272 http://dx.doi.org/10.3390/jcm12165230 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Hannemann, Juliane Thorarinnsdottir, Elin H. Amaral, André F. S. Schwedhelm, Edzard Schmidt-Hutten, Lena Stang, Heike Benediktsdottir, Bryndis Gunnarsdóttir, Ingibjörg Gislason, Thórarinn Böger, Rainer Biomarkers of the L-Arginine/Dimethylarginine/Nitric Oxide Pathway in People with Chronic Airflow Obstruction and Obstructive Sleep Apnoea |
title | Biomarkers of the L-Arginine/Dimethylarginine/Nitric Oxide Pathway in People with Chronic Airflow Obstruction and Obstructive Sleep Apnoea |
title_full | Biomarkers of the L-Arginine/Dimethylarginine/Nitric Oxide Pathway in People with Chronic Airflow Obstruction and Obstructive Sleep Apnoea |
title_fullStr | Biomarkers of the L-Arginine/Dimethylarginine/Nitric Oxide Pathway in People with Chronic Airflow Obstruction and Obstructive Sleep Apnoea |
title_full_unstemmed | Biomarkers of the L-Arginine/Dimethylarginine/Nitric Oxide Pathway in People with Chronic Airflow Obstruction and Obstructive Sleep Apnoea |
title_short | Biomarkers of the L-Arginine/Dimethylarginine/Nitric Oxide Pathway in People with Chronic Airflow Obstruction and Obstructive Sleep Apnoea |
title_sort | biomarkers of the l-arginine/dimethylarginine/nitric oxide pathway in people with chronic airflow obstruction and obstructive sleep apnoea |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10455103/ https://www.ncbi.nlm.nih.gov/pubmed/37629272 http://dx.doi.org/10.3390/jcm12165230 |
work_keys_str_mv | AT hannemannjuliane biomarkersofthelargininedimethylargininenitricoxidepathwayinpeoplewithchronicairflowobstructionandobstructivesleepapnoea AT thorarinnsdottirelinh biomarkersofthelargininedimethylargininenitricoxidepathwayinpeoplewithchronicairflowobstructionandobstructivesleepapnoea AT amaralandrefs biomarkersofthelargininedimethylargininenitricoxidepathwayinpeoplewithchronicairflowobstructionandobstructivesleepapnoea AT schwedhelmedzard biomarkersofthelargininedimethylargininenitricoxidepathwayinpeoplewithchronicairflowobstructionandobstructivesleepapnoea AT schmidthuttenlena biomarkersofthelargininedimethylargininenitricoxidepathwayinpeoplewithchronicairflowobstructionandobstructivesleepapnoea AT stangheike biomarkersofthelargininedimethylargininenitricoxidepathwayinpeoplewithchronicairflowobstructionandobstructivesleepapnoea AT benediktsdottirbryndis biomarkersofthelargininedimethylargininenitricoxidepathwayinpeoplewithchronicairflowobstructionandobstructivesleepapnoea AT gunnarsdottiringibjorg biomarkersofthelargininedimethylargininenitricoxidepathwayinpeoplewithchronicairflowobstructionandobstructivesleepapnoea AT gislasonthorarinn biomarkersofthelargininedimethylargininenitricoxidepathwayinpeoplewithchronicairflowobstructionandobstructivesleepapnoea AT bogerrainer biomarkersofthelargininedimethylargininenitricoxidepathwayinpeoplewithchronicairflowobstructionandobstructivesleepapnoea |